Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Red cell tranfusion may increase risk of postsurgical VTE

Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

Key clinical point: RBC transfusions were associated with development of postoperative venous thromboembolism (VTE).

Major finding: Patients who received perioperative RBC transfusions had significantly increased odds of developing VTE in the 30-day postoperative period (adjusted odds ratio, 2.1; 95% confidence interval, 2.0-2.3), compared with patients who did not receive transfusions.

Study details: An analysis of prospectively collected North American registry data including 750,937 patients who underwent a surgical procedure in 2014.

Disclosures: The study was funded in part by grants from the National Institutes of Health and Cornell University, New York. The researchers reported having no conflicts of interest.

Source: Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565.

Read the full story here.

Citation:

Goel R et al. JAMA Surg. 2018 Jun 13. doi: 10.1001/jamasurg.2018.1565

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Bleeding Disorders

Durable responses for hemophilia A gene therapy, High K et al. ASH 2018, Abstract 487

A clot lysis contradiction with mild bleeding, Vries MJA et al. Thromb Res. 2018 Dec 4. doi: 10.1016/j.thromres.2018.12.004

Factor VIII inhibitors seen in some patient subgroups, not others, Gangadharan B et al. ASH 2018, Poster 3774

Could thrombin generation be a better biomarker?, Nossair F et al. ASH 2018, Poster 3788

Novoeight looks safe in hemophilia A extension trial, Lentz SR et al. Haemophilia. 2018 Nov;24(6):e391-e394